Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean M Devlin

Showing results (61-70 of 173) with videos related to

Pageof 18
Sort By:
Haematologica|October 15, 2020
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemiaMark B Geyer, Ellen K Ritchie, Arati V Rao, et al.
Journal of Neurotrauma|February 21, 2014
Addressing the challenges of obtaining functional outcomes in traumatic brain injury research: missing data patterns, timing of follow-up, and three prognostic modelsLeila R Zelnick, Laurie J Morrison, Sean M Devlin, et al.
JCI Insight|April 3, 2019
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLLMark B Geyer, Isabelle Rivière, Brigitte Sénéchal, et al.
Transplantation and Cellular Therapy|October 14, 2020
Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease ProphylaxisAndrew Lin, Jessica Flynn, Lauren DeRespiris, et al.
Cell Stem Cell|August 15, 2017
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCatherine C Coombs, Ahmet Zehir, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2014
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphomaParastoo B Dahi, Roni Tamari, Sean M Devlin, et al.
Leukemia & Lymphoma|December 6, 2024
A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantationJoshua A Fein, Agnes McAuliffe, Kimberly Fischer, et al.
Bone Marrow Transplantation|May 15, 2020
Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphomaRichard J Lin, Caleb Ho, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 10, 2013
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patientsCraig S Sauter, Juliet N Barker, Lauren Lechner, et al.
Transplantation and Cellular Therapy|July 2, 2021
Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft RecipientsRoni Tamari, Samantha Brown, Sean M Devlin, et al.
Pageof 18

Showing results (61-70 of 173) with videos related to

Sort By:
Pageof 18
Haematologica|October 15, 2020
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemiaMark B Geyer, Ellen K Ritchie, Arati V Rao, et al.
Journal of Neurotrauma|February 21, 2014
Addressing the challenges of obtaining functional outcomes in traumatic brain injury research: missing data patterns, timing of follow-up, and three prognostic modelsLeila R Zelnick, Laurie J Morrison, Sean M Devlin, et al.
JCI Insight|April 3, 2019
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLLMark B Geyer, Isabelle Rivière, Brigitte Sénéchal, et al.
Transplantation and Cellular Therapy|October 14, 2020
Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease ProphylaxisAndrew Lin, Jessica Flynn, Lauren DeRespiris, et al.
Cell Stem Cell|August 15, 2017
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical OutcomesCatherine C Coombs, Ahmet Zehir, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2014
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphomaParastoo B Dahi, Roni Tamari, Sean M Devlin, et al.
Leukemia & Lymphoma|December 6, 2024
A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantationJoshua A Fein, Agnes McAuliffe, Kimberly Fischer, et al.
Bone Marrow Transplantation|May 15, 2020
Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphomaRichard J Lin, Caleb Ho, Sean M Devlin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 10, 2013
A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patientsCraig S Sauter, Juliet N Barker, Lauren Lechner, et al.
Transplantation and Cellular Therapy|July 2, 2021
Fractionated Infusion of Hematopoietic Progenitor Cells Does Not Improve Neutrophil Recovery or Survival in Allograft RecipientsRoni Tamari, Samantha Brown, Sean M Devlin, et al.
Pageof 18